![2019 09 05 21 14 7857 Heart Pulmonary Trunk 400](https://img.labpulse.com/files/base/smg/all/image/2022/01/lp.2019_09_05_21_14_7857_heart_pulmonary_trunk_400.png?auto=format%2Ccompress&q=70&w=400)
PierianDx and Biodesix announced that they will be partnering in the development of lung cancer diagnostics based on next-generation sequencing (NGS) technology.
PierianDx will provide its interpretation technology platform for use with Biodesix's newly launched GeneStrat NGS genomic test, a blood-based tumor profiling test that detects mutations -- including EGFR, ALK, and KRAS -- in patients with non-small cell lung cancer (NSCLC).
The GeneStrat NGS test is a key part of the IQLung platform that aims to measure tumor-specific mutations and patient immune profiles with results in 72 hours.